Michael R Lindberg, Ashley DiLorenzo, Jennifer A DeSimone
Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL...
January 2023: Cutis; Cutaneous Medicine for the Practitioner
Ajil Shaji, Pavithran Keechilat, Vijaykumar Dk, Catherine Sauvaget
PURPOSE: Cancer mortality trends have not been documented across the population of India. We, therefore, analyzed the overall and individual cancer mortality trends for 23 major cancers between 2000 and 2019 on the basis of Global Health Observatory (GHO) database. MATERIALS AND METHODS: This study examined cancer mortality trends for 23 major cancer sites on the basis of 12.85 million cancer deaths obtained from the GHO of the WHO between 2000 and 2019. A joinpoint regression model was used to analyze the long-term trends of cancer mortality...
March 2023: JCO global oncology
Susan K Parsons, Kristina S Yu, Nicholas Liu, Supriya Kumar, Michelle A Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R Flora, Andrew M Evens
PURPOSE: We surveyed oncologists who treat classic Hodgkin lymphoma (cHL) as part of the CONNECT study to understand the treatment decision-making process, including the impact of positron emission tomography/computed tomography (PET/CT) imaging. METHODS: US physicians self-identifying as oncologists, hematologists, or hematologists/oncologists with ≥2 years of practice experience who treated ≥1 adult with stage III/IV cHL in the frontline setting in the last year were surveyed (October 19-November 16, 2020)...
March 22, 2023: JCO oncology practice
Ghada M Ezzat, Ahmed Y Nassar, Marwa H Bakr, Shimma Mohamed, Gamal A Nassar, Amira A Kamel
Multiple organs, including the testes, are damaged by iron overload. It has been shown that N-acetyl cysteine (NAC) influences oxidative stress in iron overload. The present study aimed to evaluate the roles of acetylated peptide (AOP) and NAC in the inhibition of iron-overload induced-testicular damage. At the beginning of the experiment, NAC (150 mg /kg) was given for a week to all 40 rats. Then, four groups were formed by dividing the animals (10 rats/group). Group I included healthy control rats. Group II (iron overload) was given intraperitoneal iron dextran (60 mg/kg/day) 5 days a week for 4 weeks...
March 22, 2023: Applied Biochemistry and Biotechnology
Christopher Parker, Fei Fei Liu, Kristen A Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J Keating, Sonja Sorensen
INTRODUCTION: The objective of this study was to evaluate the cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus other available chimeric antigen receptor T-cell therapies, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), in patients who had received at least two prior therapies from a United States (US) commercial third-party payer perspective. METHODS: To capture this heterogeneity in survival outcomes, we used mixture cure models to extrapolate progression-free survival (PFS) and overall survival (OS)...
March 22, 2023: Advances in Therapy
Zhixin Sheng, Dianfang Li, Bing Chen, Chunwu Zhao, Wenxing Zhang, Baolong Ding, Lida Wang
Because of lacking of head-to-head comparison among polatuzumab (Pola) vedotin and other novel agents for untreated diffuse large B-cell lymphoma (DLBCL), the optimal option remains undefined. We searched twelve relevant published reports, covering 8376 subjects. Interestingly, the PFS benefit with Pola-R-CHP over other regimens was found prominently in those B-cell-like type (ABC-type) patients. For those ABC-type patients, the PFS advantage with Pola-R-CHP was statistically significant, when compared to R-CHOP+Bort (HR: 0...
March 22, 2023: Annals of Hematology
Maciej Tatarczuch, Mark Waltham, Jake Shortt, Galina Polekhina, Eliza A Hawkes, Shir-Jing Ho, Judith Trotman, Daniella Brasacchio, Melannie Co, Jessica Li, Vanitha Ramakrishnan, Karin Dunne, Stephen S Opat, Gareth P Gregory
Utilising tissue whole exome sequencing (WES) and circulating tumor cell-free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group (ALLG) translational study sought to characterise primary and acquired molecular determinants of response and resistance of MZL to zanubrutinib for patients treated on the MAGNOLIA clinical trial. WES was performed on baseline tumor samples obtained from 18 patients. For seven patients, ctDNA was interrogated using a bespoke hybrid-capture next-generation sequencing (NGS) assay for 48 targeted genes...
March 22, 2023: Blood Advances
Daniel R Rissi, Anne C Avery, Robert C Burnett
T-cell-rich, large B-cell lymphoma (TCRLBCL) is the most commonly diagnosed type of lymphoma in horses. Here we describe the clinical signs, neuropathology, immunohistochemistry (IHC), and PCR for antigen receptor rearrangement (PARR) analysis results of a TCRLBCL in the brain of an 8-y-old male Quarter Horse that was euthanized after acute anorexia, tremors, head pressing, falling, blindness, incoordination, and seizures. Autopsy revealed a firm, smooth, pale-yellow mass that expanded both lateral ventricles and the adjacent subcortical white matter...
March 22, 2023: Journal of Veterinary Diagnostic Investigation
Justin C Crane, Max J Gordon, Karen Basen-Engquist, Alessandra Ferrajoli, Melissa M Markofski, Che Young Lee, Sara Fares, Richard J Simpson, Emily C LaVoy
OBJECTIVE: Examine physical function and T-cell phenotype in patients with chronic lymphocytic leukemia (CLL) before and after a physical activity (PA) intervention. METHODS: Physical function measures and blood samples were collected from CLL patients (Rai stage 0-4, 50% receiving targeted therapy, N=24) enrolled in a 16-week intervention of at-home aerobic and/or resistance exercise. Flow cytometry characterized T-cells in cryopreserved peripheral blood cells...
March 22, 2023: European Journal of Haematology
Haiyan Zhou, Lihong Zhou, Caixia Zhang, Li Zhou, Yuhua Han
Objective To explore the effects of microRNA-155-5p (miR-155-5p) on lipopolysaccharide (LPS)-induced neuroinflammatory damage of human SH-SY5Y neuroblastoma cells. Methods SH-SY5Y cells line was overexpressed miR-155-5p or transfected with negative control (miR-155-5p mimic group, mimic-NC group), down-expressed miR-155-5p or transfected with its negative control (miR-155-5p inhibitor group, inhibitor-NC group). The cells with successful transfection in the above groups were treated with LPS for 24 hours. The cells without SH-SY5Y cells transfection and those with LPS treatment were included into control group and LPS group, respectively...
March 2023: Xi Bao Yu Fen Zi Mian Yi Xue za Zhi, Chinese Journal of Cellular and Molecular Immunology
Zhuo Wu, Ziran Li, Xiaoyan Qiu, Mingkang Zhong, Tianling Ding
BACKGROUND: : High-dose methotrexate (HD-MTX)-based regimens are the standard treatment for patients with primary central nervous system lymphoma (PCNSL); however, MTX has extensive interpatient variability in pharmacokinetics and clinical outcomes, with genetic variation an important factor involved in the variability in drug response. METHODS: 123 PCNSL patients who received 524 courses of chemotherapy were genotyped for 42 single nucleotide polymorphisms in MTX pathway...
March 22, 2023: Expert Review of Clinical Pharmacology
Suheil Albert Atallah-Yunes, Omar Salman, Michael J Robertson
Post-transplant lymphoproliferative disorder (PTLD) is rare and heterogeneous lymphoid proliferations that occur as a result of immunosuppression following solid organ transplant (SOT) and haematopoietic stem cell transplant (HSCT) with the majority being driven by EBV. Although some histologies are similar to lymphoid neoplasms seen in immunocompetent patients, treatment of PTLD may be different due to difference in pathobiology and higher risk of treatment complications. The most common treatment approach in SOT PTLD after failing immunosuppression reduction (RIS) takes into consideration a risk-stratified sequential algorithm with rituximab +/- chemotherapy based on phase 2 studies...
March 22, 2023: British Journal of Haematology
Kana Miyata-Morita, Shigeki Morita, Hitoshi Dejima, Koji Saito, Yukinori Sakao, Makoto Mochizuki, Yuko Sasajima
INTRODUCTION: Cancer-associated fibroblasts (CAFs) in the tumour microenvironment play a key role in tumour development, proliferation, invasion, and metastasis. The cytological features of spindle cells including CAFs-defined as stromal spindle cells (SSCs) adjacent to cancer cells-are frequently encountered in pulmonary adenocarcinomas. This study aimed to investigate the association between the presence of SSCs in cytological specimens and the clinicopathological features. METHODS: We evaluated 211 patients with pulmonary adenocarcinoma who underwent surgical resection...
March 22, 2023: Cytopathology: Official Journal of the British Society for Clinical Cytology
Laura K Hilton, Henry S Ngu, Brett Collinge, Kostiantyn Dreval, Susana Ben-Neriah, Christopher K Rushton, Jasper C H Wong, Manuela Cruz, Andrew Roth, Merrill Boyle, Barbara Meissner, Graham W Slack, Pedro Farinha, Jeffrey W Craig, Alina S Gerrie, Ciara L Freeman, Diego Villa, Michael Crump, Lois Shepherd, Annette E Hay, John Kuruvilla, Kerry J Savage, Robert Kridel, Aly Karsan, Marco A Marra, Laurie H Sehn, Christian Steidl, Ryan D Morin, David W Scott
Diffuse large B-cell lymphoma (DLBCL) is cured in over 60% of patients, but outcomes are poor for patients with relapsed or refractory disease (rrDLBCL). Here, we performed whole genome/exome sequencing (WGS/WES) on tumors from 73 serially-biopsied patients with rrDLBCL. Based on the observation that outcomes to salvage therapy/autologous stem cell transplantation are related to time-to-relapse, we stratified patients into groups according to relapse timing to explore the relationship to genetic divergence and sensitivity to salvage immunochemotherapy...
March 8, 2023: medRxiv
Imani Bijou, Yang Liu, Dong Lu, Jianwei Chen, Shelby Sloan, Lapo Alinari, David M Lonard, Bert W O'Malley, Michael Wang, Jin Wang
Mantle cell lymphoma (MCL) is a heterogeneous disease with a poor prognosis. Despite years of research in MCL, relapse occurs in patients with current therapeutic options necessitating the development of novel therapeutic agents. Previous attempts to pharmacologically inhibit SRC-3 show effectiveness in vivo and in vitro in other B cell lymphomas, and previous studies have shown that SRC-3 is highly expressed in the lymph nodes of B cell non-Hodgkin's lymphoma patients. This suggests that SRC-3 may play a role in the progression of B cell lymphoma and that the development of selective SRC inhibitors should be investigated...
March 10, 2023: Research Square
Gita Thanarajasingam, Paul Kluetz, Vishal Bhatnagar, Abbie Brown, Elizabeth Cathcart-Rake, Matthew Diamond, Louis Faust, Mallorie Fiero, Scott Huntington, Molly Moore Jeffery, Lee Jones, Brie Noble, Jonas Paludo, Brad Powers, Joseph S Ross, Jessica Ritchie, Kathryn Ruddy, Sarah Schellhorn, Michelle Tarver, Amylou Dueck, Cary Gross
Introduction Accurate, patient-centered evaluation of physical function in patients with cancer can provide important information on the functional impacts experienced by patients both from the disease and its treatment. Increasingly, digital health technology is facilitating and providing new ways to measure symptoms and function. There is a need to characterize the longitudinal measurement characteristics of physical function assessments, including clinician reported physical function (ClinRo), patient-reported physical function (PRO), performance outcome tests (PerfO) and wearable data, to inform regulatory and clinical decision making in cancer clinical trials and oncology practice...
March 9, 2023: medRxiv
Fernando Nogueira, Isabel C Brito, Catarina V Pereira, José C Marques, Ester Ferreira, Ana Carneiro
Haemophagocytic lymphohistiocytosis is a syndrome of excessive immunological activation that can be triggered by various diseases, including haematological cancers. We report a case of a 25-year-old woman presenting with constitutional symptoms and a painful thoracic mass of four months duration. Laboratory exams showed pancytopenia, hypertriglyceridemia and extremely high serum ferritin levels. A whole-body computed tomography (CT) scan revealed splenomegaly and highlighted the mass on the deep tissues of the left breast; the biopsy was compatible with anaplastic large-cell lymphoma...
February 2023: Curēus
Shingo Kawano, Kimi Araki, Jie Bai, Imari Furukawa, Keigo Tateishi, Kumiko Yoshinobu, Shingo Usuki, Rachael A Nimmo, Tadashi Kaname, Masaharu Yoshihara, Satoru Takahashi, Goro Sashida, Masatake Araki
MicroRNAs (miRNAs) play a crucial role in regulating gene expression. miRNA expression levels fluctuate, and point mutations and methylation occur in cancer cells; however, to date, there are no reports of carcinogenic point mutations in miRNAs. MicroRNA-142 (miR-142) is frequently mutated in patients with follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). To understand the role of miR-142 mutation in blood cancers, the CRISPR-Cas9 system was utilized to successfully generate miR-142-55A>G mutant knock-in (Ki) mice, simulating the most frequent mutation in patients with miR-142 mutated AML/MDS...
March 21, 2023: Cancer Science
Na Niu, Meghan M Heberton, Zhenya Tang, Phyu P Aung, Priyadharsini Nagarajan, Jonathan L Curry, Victor G Prieto, Carlos A Torres-Cabala, Woo Cheal Cho
Lymphomatoid papulosis (LyP) with DUSP22-IRF4 rearrangement is a rare, recently described variant of LyP histopathologically characterized by a biphasic growth pattern, with epidermotropic small-to-medium-sized atypical T-cells and dermal large and transformed T-cells diffusely expressing CD30. LyP with DUSP22-IRF4 rearrangement can mimic other cutaneous lymphoproliferative disorders, particularly primary cutaneous anaplastic large cell lymphoma (PCALCL) or transformed mycosis fungoides (MF). Unlike PCALCL or transformed MF, LyP with DUSP22-IRF4 rearrangement shows an indolent clinical behavior, with frequent spontaneous regression of untreated lesions...
March 21, 2023: Journal of Cutaneous Pathology
Christopher Alan Brooks, John David Kehoe, Neal Kerr, Fouzia Ziad, Sami Raunio
Lymphoma of a dural genesis is a distinct variant of primary central nervous system lymphoma and is rare. It putatively has a more benign clinical course. Cranial primary dural lymphoma is more often marginal zone B-cell lymphoma, whereas spinal primary dural lymphoma is most commonly diffuse large B-cell lymphoma.We report a male patient who presented with subacute progressive radiculopathy due to a compressive infiltrative lumbosacral spinal lesion. This was determined to be primary dural diffuse large B-cell lymphoma...
March 21, 2023: BMJ Case Reports
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.